Teriparatide

Teriparatide (Forteo) is a synthetic fragment of human parathyroid hormone containing the first 34 amino acids (PTH 1-34). Approved by the FDA in 2002, it was the first anabolic (bone-building) drug for osteoporosis, representing a fundamentally different approach than existing treatments that merely slowed bone loss.

Parathyroid hormone might seem like an unlikely osteoporosis treatment—chronically elevated PTH (as in hyperparathyroidism) actually causes bone loss. The key insight was that intermittent PTH exposure, through once-daily injection, produces anabolic effects by preferentially stimulating bone-building osteoblasts. This pulsatile approach creates a pharmacological profile opposite to the continuous PTH elevation that causes bone damage.

Teriparatide is particularly valuable for severe osteoporosis with high fracture risk, patients who have fractured despite other treatments, or situations requiring rapid bone improvement. It increases bone density by actually forming new bone tissue, improving bone quality and strength in ways anti-resorptive drugs cannot match.

Teriparatide's anabolic effect depends on its intermittent dosing pattern, which creates a brief daily pulse of PTH activity.

Anabolic vs. Catabolic PTH

Continuous PTH elevation stimulates both osteoblasts (bone formation) and osteoclasts (bone resorption), with resorption predominating—resulting in bone loss. Intermittent PTH (brief daily pulse from injection) preferentially activates osteoblasts, with anabolic signaling persisting after PTH clears while the shorter-lived catabolic signals fade. This creates net bone formation.

Cellular Effects

Teriparatide activates PTH receptors on osteoblasts, triggering:

• Increased osteoblast differentiation and activity
• Reduced osteoblast apoptosis (longer cell survival)
• Increased bone matrix production
• Stimulation of factors promoting bone formation

Bone Quality

Beyond density increases, teriparatide improves bone microarchitecture—trabecular connectivity, cortical thickness, and structural integrity. This quality improvement may explain why fracture reduction exceeds what density changes alone would predict.

Teriparatide has extensive clinical trial data supporting its efficacy for osteoporosis and fracture prevention.

Pivotal Trials

The Fracture Prevention Trial demonstrated 65% reduction in new vertebral fractures and 53% reduction in non-vertebral fractures over 21 months. Bone mineral density increased 9% in the spine and 3% in the hip—among the largest increases for any osteoporosis treatment.

Comparison Studies

Head-to-head trials have shown teriparatide superior to bisphosphonates for increasing bone density and reducing vertebral fractures, particularly in severe osteoporosis.

Fracture Healing

Research has explored teriparatide for accelerating fracture healing, with promising results for difficult fractures and nonunions, though this remains an off-label application.

Teriparatide is administered as a once-daily subcutaneous injection.

Standard Dosing

• Dose: 20 mcg once daily
• Route: Subcutaneous (thigh or abdomen)
• Duration: Up to 2 years cumulative lifetime exposure (FDA guideline)

Administration

Forteo comes in a pre-filled multi-dose pen for easy self-administration. Inject at the same time daily; can be given at any time regardless of meals.

After Teriparatide

Following teriparatide, patients typically transition to anti-resorptive therapy (bisphosphonates or denosumab) to maintain bone gains.

Teriparatide has a well-characterized safety profile from clinical trials and years of post-marketing surveillance.

Common Effects

• Leg cramps (~3%)
• Nausea
• Dizziness (orthostatic)
• Headache
• Injection site reactions

Boxed Warning

The boxed warning regarding osteosarcoma (bone cancer) is based on rat studies using high doses. Post-marketing surveillance in humans has not confirmed this risk. The 2-year treatment limit reflects regulatory caution rather than observed human risk.

Contraindications

Avoid in patients with: elevated baseline calcium, bone metastases or history of bone malignancy, Paget's disease, unexplained alkaline phosphatase elevation, prior radiation involving bone.